Pharmacokinetics and safety of rifabutin in young hiv-infected children receiving rifabutin and lopinavir/ritonavir

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 2, 2015, Pages 543-549

  Moultrie, Harry ^a   Mcilleron, Helen ^b   Sawry, Shobna ^a   Kellermann, Tracy ^b   Wiesner, Lubbe ^b   Kindra, Gurpreet ^a   Gous, Hermien ^a   van Rie, Annelies ^c  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c IL   (United States)

Author keywords

TB; Treatment; Tuberculosis

Indexed keywords

25 O DESACETYL RIFABUTIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; COTRIMOXAZOLE; CREATININE; LOPINAVIR PLUS RITONAVIR; RIFABUTIN; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; UREA; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LOPINAVIR; RITONAVIR; TUBERCULOSTATIC AGENT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG ABSORPTION; DRUG HALF LIFE; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE DIFFERENTIAL COUNT; MAXIMUM PLASMA CONCENTRATION; MEDICATION COMPLIANCE; MYALGIA; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; OPTIMAL DRUG DOSE; PATIENT COMPLIANCE; PRESCHOOL CHILD; SHORT COURSE THERAPY; SIDE EFFECT; SOUTH AFRICA; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UREA BLOOD LEVEL; UVEITIS; CLINICAL TRIAL; COINFECTION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; INFANT; MALE; TREATMENT OUTCOME; TUBERCULOSIS; VIROLOGY;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; CHILD, PRESCHOOL; COINFECTION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INFANT; LOPINAVIR; MALE; RIFABUTIN; RITONAVIR; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84922455222     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku382     Document Type: Article

References (32)

1. Meyers TM, Yotebieng M, Kuhn L et al. Antiretroviral therapy responses among children attending a large public clinic in Soweto, South Africa. Pediatr Infect Dis J 2011; 30: 974-9.
2. WHO. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. Geneva: WHO, 2013.
3. Violari A, Lindsey JC, Hughes MD et al. Nevirapine versus ritonavirboosted lopinavir for HIV-infected children. N Engl J Med 2012; 366: 2380-9.
4. Palumbo P, Lindsey JC, Hughes MD et al. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med 2010; 363: 1510-20.
5. Oudijk JM, McIlleron H, Mulenga V et al. Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment. AIDS 2012; 26: 1523-8.
6. ARROW Trial team, Kekitiinwa A, Cook A et al. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. Lancet 2013; 381: 1391-403.
7. Kuhn L, Coovadia HM. Monitoring strategies for management of ART in children. Lancet 2013; 381: 1343-4.
8. McIlleron H, Ren Y, Nuttall J et al. Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis. Antivir Ther 2011; 16: 417-21.
9. Ren Y, Nuttall JJ, Egbers C et al. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr 2008; 47: 566-9.
10. CDC. Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis. 2013. http://www.cdc.gov/tb/publications/guidelines/ tb_hiv_drugs/pdf/tbhiv.pdf.
11. WHO. The Selection and Use of Essential Medicines: Report of the WHO Expert Committee, March 2009 (Including the 16th WHO Model List of Essential Medicines and the 2nd WHO Model List of Essential Medicines for Children). Geneva: WHO, 2009.
12. Abbott Pharmaceuticals. Kaletra Product Information. www.ema. europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/ human/000368/WC500039043.pdf.
13. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. http:// aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
14. Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 2001; 40: 327-41.
15. Griffith DE, Brown BA,Wallace RJ Jr. Varying dosages of rifabutin affect white blood cell and platelet counts in human immunodeficiency virus- negative patients who are receiving multidrug regimens for pulmonary Mycobacterium avium complex disease. Clin Infect Dis 1996; 23: 1321-2.
16. Davies G, Cerri S, Richeldi L. Rifabutin for treating pulmonary tuberculosis. Cochrane Database Syst Rev 2007; issue 4: CD005159.
17. Ford SL, Chen YC, Lou Y et al. Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects. Antimicrob Agents Chemother 2008; 52: 534-8.
18. Boulanger C, Hollender E, Farrell K et al. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis 2009; 49: 1305-11.
19. Naiker S, Conolly C, Weisner L et al. Pharmacokinetic evaluation of different rifabutin dosing strategies in African TB patients on lopinavir/ ritonavir-based ART. In: Abstracts of the Eighteenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2011. Abstract 650. Foundation for Retrovirology and Human Health, Alexandra, VA, USA.
20. del Rio C. Updated guidelines for the use of rifamycins in HIV/TB-coinfected patients. AIDS Clin Care 2004; 16: 85.
21. Anderson BJ, Holford NH.Mechanism-based concepts of size andmaturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008; 48: 303-32.
22. Haslam JL, Egodage KL, Chen Yet al. Stability of rifabutin in two extemporaneously compounded oral liquids. Am J Health Syst Pharm 1999; 56: 333-6.
23. WHO. Antiretroviral Therapy for HIV Infection in Infants and Children: Towards Universal Access-2010 Revision. Geneva: WHO, 2010.
24. NIH. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, December, 2004; Clarification August 2009. http://rsc.tech-res.com/Document/safetyandpharmacovigilance/Table_ for_Grading_Severity_of_Adult_Pediatric_Adverse_Events.pdf.
25. WHO Multicentre Growth Reference Study Group. WHO Child Growth Standards: Length/Height-for-Age, Weight-for-Age, Weight-for-Length, Weight-for-Height and Body Mass Index-for-Age: Methods and Development. Geneva: WHO, 2006.
26. Department of Health. Guidelines for the Management of HIV in Children, 2010. Pretoria: South African National Department of Health, 2010.
27. NIAID. Division of AIDS (DAIDS) Table for Grading Severity of Pediatric (3 Months of Age) Adverse Experiences, April 1994. http://rsc.tech-res. com/Document/safetyandpharmacovigilance/Table_for_Grading_Severity_ of_Pediatric_AEs_Over3MonthsAge_v03.pdf.
28. Lan NT, Thu NT, Barrail-Tran A et al. Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam. PLoS One 2014; 9: e84866.
29. Anderson BJ, Holford NH. Understanding dosing: children are small adults, neonates are immature children. Arch Dis Child 2013; 98: 737-44.
30. Wells J, Shetty AK, Stranix L et al. Range of normal neutrophil counts in healthy Zimbabwean infants: implications for monitoring antiretroviral drug toxicity. J Acquir Immune Defic Syndr 2006; 42: 460-3.
31. Kourtis AP, Bramson B, van der Horst C et al. Low absolute neutrophil counts in African infants. J Int Assoc Physicians AIDS Care (Chic) 2005; 4: 73-6.
32. Haddy TB, Rana SR, Castro O. Benign ethnic neutropenia: what is a normal absolute neutrophil count? J Lab Clin Med 1999; 133: 15-22.